Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Several Phase 1 and Phase 2 trials report encouraging results this month, amplifying momentum in precision psychiatry, respiratory …
Researchers propose a new framework that combines domestic real-world data with overseas trial data to make global clinical …
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
Already a subscriber? Log in